<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="964">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148598</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-II, 2021-03.V1</org_study_id>
    <nct_id>NCT05148598</nct_id>
  </id_info>
  <brief_title>ADRCs in The Treatment of Hand Dysfunction Due to Scleroderma</brief_title>
  <acronym>STAR-II</acronym>
  <official_title>Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paracrine, INC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paracrine, INC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and efficacy of the Celution&#xD;
      Device in the processing of an autologous graft consisting of adipose derived regenerative&#xD;
      cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to assess the safety and efficacy of the Celution&#xD;
      Device in the processing of an autologous graft consisting of adipose derived regenerative&#xD;
      cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2022</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective&#xD;
Randomized Parallel Group&#xD;
Placebo-Controlled&#xD;
Safety and Efficacy Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo is visually indistinguishable from active treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cochin Hand Function Score</measure>
    <time_frame>26 weeks</time_frame>
    <description>Cochin Hand Function Score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Scleroderma, Diffuse</condition>
  <arm_group>
    <arm_group_label>ADRC Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the ADRC arm will receive standard care and active treatment (ADRCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects in the Standard Care arm will receive standard care and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ADRCs</intervention_name>
    <description>Adipose Derived Regenerative Cells (ADRCs) processed with Celution System</description>
    <arm_group_label>ADRC Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Standard care</description>
    <arm_group_label>ADRC Arm</arm_group_label>
    <arm_group_label>Standard Care Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo visually indistinguishable from ADRCs</description>
    <arm_group_label>Standard Care Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diffuse cutaneous scleroderma (duration &gt; 5 years)&#xD;
&#xD;
          -  Cochin Hand Function Scale â‰¥ 20 units&#xD;
&#xD;
          -  Symptoms consistent with Raynaud's Phenomenon&#xD;
&#xD;
          -  Ability to safely undergo liposuction&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Contracture(s) of any finger&#xD;
&#xD;
          -  Sympathectomy within 6 months of Screening Visit&#xD;
&#xD;
          -  Rheumatoid Arthritis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 20, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hand Dysfunction</keyword>
  <keyword>Scleroderma</keyword>
  <keyword>Scleroderma, Diffuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data (IPD) will not be made available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

